Cytokinetics, Incorporated Board of Directors

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Mr. Robert I. Blum

Mr. Robert I. Blum

CEO, President & Director

Mr. Matt Yang

Mr. Matt Yang

Vice President of Corporate Finance and Financial Planning & Analysis

Mr. Jeff Lotz

Mr. Jeff Lotz

Vice President of Sales & Operations

Mr. Sung H. Lee

Mr. Sung H. Lee

Executive VP, Principal Financial & Accounting Officer and CFO

Ms. Kari K. Loeser J.D.

Ms. Kari K. Loeser J.D.

VP & Chief Compliance Officer

Mr. John O. Faurescu Esq.

Mr. John O. Faurescu Esq.

VP, Associate General Counsel & Corporate Secretary

Mr. Steven M. Cook J.D.

Mr. Steven M. Cook J.D.

Senior Vice President of Global Supply Chain Operations & Technical Operations

Dr. Fady Ibraham Malik FACC, M.D., Ph.D.

Dr. Fady Ibraham Malik FACC, M.D., Ph.D.

Executive Vice President of Research & Development

Mr. Andrew M. Callos

Mr. Andrew M. Callos

Executive VP & Chief Commercial Officer

Dr. James A. Spudich Ph.D.

Dr. James A. Spudich Ph.D.

Co-Founder & Member of Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.